Sector News

Edwards Announces Board Change

October 6, 2014
Life sciences
/PRNewswire/ – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that David E.I. Pyott, a member of the company’s Board of Directors, has submitted his resignation, effective today, in order to devote more time to his role as chairman and chief executive officer of Allergan, Inc.
 
“The board and I are truly appreciative of David’s service and commitment to Edwards during the last 14 years,” said Michael A. Mussallem, Edwards’ chairman and CEO.  “David’s extensive global experience in leadership roles at innovative health and nutrition companies made him a valuable resource for our company.  He has been a trusted partner and brought important expertise to Edwards in delivering novel therapies to address the needs of patients.  We wish him the best and thank him for the significant role he has played in Edwards’ growth and success.”
 
Pyott joined Edwards’ board of directors in 2000, when Edwards was established as an independent, publicly-held corporation.
 
Source: Edwards Lifesciences Corporation

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.